Q2 EPS Forecast for ARS Pharmaceuticals Reduced by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at William Blair reduced their Q2 2025 earnings per share estimates for shares of ARS Pharmaceuticals in a research report issued on Wednesday, May 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.32). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals' Q3 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.62) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.63) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million.

Several other equities research analysts also recently commented on the stock. Scotiabank started coverage on shares of ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target for the company. Oppenheimer assumed coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $31.00.

ARS Pharmaceuticals Trading Down 0.8%

Shares of SPRY traded down $0.11 during midday trading on Monday, hitting $14.22. The stock had a trading volume of 1,452,711 shares, compared to its average volume of 1,239,209. The business has a 50-day simple moving average of $13.43 and a two-hundred day simple moving average of $12.87. The firm has a market cap of $1.40 billion, a P/E ratio of -27.88 and a beta of 0.84. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of ARS Pharmaceuticals by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock worth $1,722,000 after purchasing an additional 917 shares in the last quarter. Rhumbline Advisers raised its position in ARS Pharmaceuticals by 2.9% during the fourth quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after acquiring an additional 1,824 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in ARS Pharmaceuticals by 10.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company's stock valued at $217,000 after acquiring an additional 1,962 shares during the last quarter. Mariner LLC grew its position in ARS Pharmaceuticals by 5.8% in the fourth quarter. Mariner LLC now owns 35,908 shares of the company's stock worth $379,000 after acquiring an additional 1,972 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in ARS Pharmaceuticals by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 132,213 shares of the company's stock worth $1,663,000 after acquiring an additional 1,975 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company's stock.

Insider Activity

In other news, insider Eric Karas sold 10,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now directly owns 7,696 shares in the company, valued at $107,744. The trade was a 56.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Laura Shawver sold 49,600 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the sale, the director now owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,602 shares of company stock worth $1,311,041 in the last 90 days. Company insiders own 33.50% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.